Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947685 | 0.82 | DYRK1B (0.41) | DYRK1BPARP1DYRK1ADYRK2CDK2 | |
| SCHEMBL2490928 | 0.75 | CCNA2 (0.48) | DYRK1BDYRK1ADYRK2CDK2CDK5 | |
| SCHEMBL13039420 | 0.74 | CDC7 (0.47) | CDK2CCNT1CCNA2CDK9CCNA1 | |
| SCHEMBL3250098 | 0.72 | MAPT (0.39) | DYRK1BDYRK1ACDK2CDK5CCNT1 | |
| SCHEMBL13039430 | 0.70 | DHODH (0.46) | CDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL5090972 | 0.69 | JAK3 (0.37) | DYRK1B | |
| SCHEMBL13039399 | 0.69 | EIF2AK2 (0.38) | CDK2CCNT1CCNA2CDK9CCNA1 | |
| SCHEMBL24760933 | 0.69 | CDK2 (0.34) | DYRK1BDYRK1ADYRK2CDK2CDK5 | |
| SCHEMBL3909205 | 0.69 | CYP3A4 (0.39) | DYRK1BDYRK1A | |
| SCHEMBL3917534 | 0.69 | CYP3A4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143729-A1 | COMPOUND, COMPOSITION AND FUNCTIONAL MOLECULE WITH MULTI-TARGET INHIBITING EFFECT AND USE THEREOF | 中国科学院上海药物研究所 | 2021-07-22 | — | — | WO | disclosed |
| CN-101883764-B | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases | NOVARTIS AG | 2013-11-13 | — | — | CN | disclosed |
| US-8367687-B2 | Pyrazole derivatives | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2231636-B1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS INHIBITORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| CN-101883764-A | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases | NOVARTIS AG | 2010-11-10 | — | — | CN | disclosed |
| US-20100280033-A1 | Pyrazole Derivatives | NOVARTIS AG | 2010-11-04 | — | — | US | disclosed |
| EP-2231636-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS INHIBITORS OF CYCLIN DEPENDENT KINASES | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071701-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS INHIBITORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280033-A1 | Pyrazole Derivatives | PRKDC, PRKACA, PDK2 | DYRK1B 1545/4885PARP1 1323/4885DYRK1A 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.